Technical Analysis for SVRA - Savara, Inc.

Grade Last Price % Change Price Change
D 1.63 -5.23% -0.09
SVRA closed down 5.23 percent on Friday, March 5, 2021, on approximately normal volume. It was able to find support at its 50 day moving average. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical SVRA trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Support Bullish -5.23%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.23%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.23%
Calm After Storm Range Contraction -5.23%
Older End-of-Day Signals for SVRA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Savara, Inc. Description

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Clinical Development Heart Failure Stage Pharmaceutical Cystic Fibrosis Respiratory Disease Respiratory Diseases Staphylococcus Aureus Heart Diseases Treatment Of Heart Failure Lung Infection Diastolic Heart Failure Heart Failure With Preserved Ejection Fraction Methicillin

Is SVRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.17
52 Week Low 0.9952
Average Volume 551,207
200-Day Moving Average 1.66
50-Day Moving Average 1.60
20-Day Moving Average 1.82
10-Day Moving Average 1.79
Average True Range 0.18
ADX 23.96
+DI 21.47
-DI 22.20
Chandelier Exit (Long, 3 ATRs ) 1.70
Chandelier Exit (Short, 3 ATRs ) 2.06
Upper Bollinger Band 2.06
Lower Bollinger Band 1.57
Percent B (%b) 0.12
BandWidth 26.97
MACD Line 0.02
MACD Signal Line 0.06
MACD Histogram -0.0346
Fundamentals Value
Market Cap 88.25 Million
Num Shares 54.1 Million
EPS -1.58
Price-to-Earnings (P/E) Ratio -1.03
Price-to-Sales 275.49
Price-to-Book 0.90
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.97
Resistance 3 (R3) 1.97 1.85 1.91
Resistance 2 (R2) 1.85 1.77 1.85 1.89
Resistance 1 (R1) 1.74 1.71 1.68 1.74 1.88
Pivot Point 1.63 1.63 1.60 1.63 1.63
Support 1 (S1) 1.51 1.54 1.46 1.52 1.38
Support 2 (S2) 1.40 1.49 1.40 1.37
Support 3 (S3) 1.29 1.40 1.35
Support 4 (S4) 1.29